0000000000306589

AUTHOR

Andreas Luchner

showing 4 related works from this author

Meta-Analysis of the INSIG2 Association with Obesity Including 74,345 Individuals: Does Heterogeneity of Estimates Relate to Study Design?

2009

The INSIG2 rs7566605 polymorphism was identified for obesity (BMI≥30 kg/m2) in one of the first genome-wide association studies, but replications were inconsistent. We collected statistics from 34 studies (n = 74,345), including general population (GP) studies, population-based studies with subjects selected for conditions related to a better health status (‘healthy population’, HP), and obesity studies (OB). We tested five hypotheses to explore potential sources of heterogeneity. The meta-analysis of 27 studies on Caucasian adults (n = 66,213) combining the different study designs did not support overall association of the CC-genotype with obesity, yielding an odds ratio (OR) of 1.05 (p-va…

MaleCancer ResearchobesityLIVERMedizinPROTEINBioinformatics0302 clinical medicineINSIG2GENETICS & HEREDITYPOPULATIONGenetics (clinical)METABOLIC SYNDROME0303 health scienceseducation.field_of_studyINSIG2Intracellular Signaling Peptides and ProteinsUPSTREAMMiddle AgedINSULINResearch DesignMeta-analysisFemaleLife Sciences & BiomedicineMedical GeneticsResearch ArticleEXPRESSIONAdultAdolescentlcsh:QH426-470PopulationPublic Health and EpidemiologyCOMMON GENETIC VARIANTBiologyChildhood obesity03 medical and health sciencesYoung AdultGeneticsmedicineBiochemical Phenomena Metabolism and NutritionHumansObesityeducationMolecular BiologyEcology Evolution Behavior and Systematics030304 developmental biology0604 GeneticsScience & TechnologyPolymorphism GeneticMembrane ProteinsOdds ratioBODY-MASSmedicine.diseaseObesityPOLYMORPHISMlcsh:GeneticsGenetics PopulationMetabolic syndromeBody mass index030217 neurology & neurosurgeryDevelopmental BiologyDemographyGenome-Wide Association StudyPLoS Genetics
researchProduct

Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE

2017

Conventional risk scores have not been accurate in predicting peri- and postprocedural risk of patients undergoing transcatheter aortic valve implantation (TAVI). Elevated levels of the tumor marker carbohydrate antigen 125 (CA125) have been linked to adverse outcomes after TAVI. We studied the additional value of CA125 to that of the EuroSCORE in predicting long-term mortality after TAVI.During a median follow-up of 59 weeks, 115 of 422 patients (27%) died after TAVI. Mortality was higher with elevated CA125 (30 U/mL) and EuroSCORE (median) (47% vs 20%, P.001 and 38% vs 16%, P.001, respectively). In the multivariable analysis, CA125 (30 U/mL) remained an independent predictor of mortality …

MaleLogistic euroscoremedicine.medical_specialtyPoor prognosisTranscatheter aortic610 Medicine & health030204 cardiovascular system & hematologyRisk AssessmentSeverity of Illness Index2705 Cardiology and Cardiovascular MedicineTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineProspective Studies030212 general & internal medicineAgedTumor markerbusiness.industryHazard ratioMembrane ProteinsEuroSCOREAortic Valve StenosisGeneral MedicinePrognosisConfidence intervalCA-125 AntigenRisk stratification10209 Clinic for CardiologyCardiologyFemalebusinessRevista Española de Cardiología (English Edition)
researchProduct

Mejora en la estratificación del riesgo tras el implante percutáneo de válvula aórtica mediante una combinación de marcador tumoral CA125 y EuroSCORE…

2017

ResumenIntroduccion y objetivos El rendimiento de las puntuaciones de riesgo tradicionales para predecir el riesgo tras el implante percutaneo valvula aortica (TAVI) no es adecuado. Las altas concentraciones plasmaticas de antigeno carbohidrato 125 (CA125) se han asociado a un aumento del riesgo de eventos adversos tras TAVI. En este trabajo se evalua el valor pronostico adicional del CA125 sobre la puntuacion EuroSCORE para la prediccion de riesgo a largo plazo. Metodos y resultados Durante una mediana de seguimento de 59 semanas, murieron 115 de 422 pacientes (27%) despues de la TAVI. La mortalidad fue mayor entre aquellos con CA125 elevado (> 30 U/ml) y EuroSCORE ≥ mediana (el 47 frente …

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industryMedicine030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation

2013

ObjectivesThis study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]).BackgroundRisk stratification after TAVI remains challenging. The use of biomarkers in this setting represents an unmet need.MethodsCA125 was measured in 228 patients before and after TAVI. The association with outcomes was assessed using parametric Cox regression and joint modeling for baseline and longitudinal analyses, respectively. CA125 was evaluated as logarithm transforma…

Malemedicine.medical_specialtyCardiac CatheterizationTime FactorsAortic Valve InsufficiencyMyocardial InfarctionKaplan-Meier EstimateRisk AssessmentCA125Interquartile rangeRisk FactorsInternal medicineMedicineHumansMyocardial infarctionLongitudinal StudiesRegistriesStroketranscatheter aortic valve implantationTumor markerAgedProportional Hazards ModelsAged 80 and overHeart FailureHeart Valve Prosthesis ImplantationProportional hazards modelbusiness.industryMembrane ProteinsAortic Valve Stenosismedicine.diseasejoint modelingHospitalizationStrokeLogistic ModelsTreatment OutcomeCardiovascular DiseasesHeart failureCA-125 AntigenMultivariate AnalysisCardiologybiomarkerBiomarker (medicine)FemaleprognosisbusinessCardiology and Cardiovascular MedicineMaceBiomarkersJACC: Cardiovascular Interventions
researchProduct